Last reviewed · How we verify
Anthrax Immune Globulin
Anthrax Immune Globulin is a Polyclonal immunoglobulin; passive immunotherapy Small molecule drug developed by National Institutes of Health Clinical Center (CC). It is currently FDA-approved for Inhalational anthrax (adjunctive therapy with antibiotics).
Anthrax Immune Globulin provides passive immunization by supplying antibodies that neutralize anthrax toxins and enhance clearance of Bacillus anthracis.
Anthrax Immune Globulin provides passive immunization by supplying antibodies that neutralize anthrax toxins and enhance clearance of Bacillus anthracis. Used for Inhalational anthrax (adjunctive therapy with antibiotics).
At a glance
| Generic name | Anthrax Immune Globulin |
|---|---|
| Sponsor | National Institutes of Health Clinical Center (CC) |
| Drug class | Polyclonal immunoglobulin; passive immunotherapy |
| Target | Anthrax protective antigen (PA); anthrax lethal factor (LF) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease; Immunology |
| Phase | FDA-approved |
Mechanism of action
This polyclonal immunoglobulin product contains human antibodies directed against anthrax protective antigen (PA) and lethal factor (LF), the key virulence factors of Bacillus anthracis. When administered, these antibodies bind to and neutralize anthrax toxins, preventing their cellular effects and facilitating bacterial clearance. It is used as an adjunctive therapy alongside antibiotics in inhalational anthrax infection.
Approved indications
- Inhalational anthrax (adjunctive therapy with antibiotics)
Common side effects
- Infusion-related reactions
- Hypersensitivity reactions
- Headache
- Myalgia
Key clinical trials
- Anthrax AV7909 Boost Evaluation Study (PHASE2)
- A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients
- Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) (PHASE1, PHASE2)
- Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum (PHASE1)
- Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers (PHASE1)
- Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers (PHASE1)
- Monoclonal Antibody for Treatment of Inhalation Anthrax (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anthrax Immune Globulin CI brief — competitive landscape report
- Anthrax Immune Globulin updates RSS · CI watch RSS
- National Institutes of Health Clinical Center (CC) portfolio CI
Frequently asked questions about Anthrax Immune Globulin
What is Anthrax Immune Globulin?
How does Anthrax Immune Globulin work?
What is Anthrax Immune Globulin used for?
Who makes Anthrax Immune Globulin?
What drug class is Anthrax Immune Globulin in?
What development phase is Anthrax Immune Globulin in?
What are the side effects of Anthrax Immune Globulin?
What does Anthrax Immune Globulin target?
Related
- Drug class: All Polyclonal immunoglobulin; passive immunotherapy drugs
- Target: All drugs targeting Anthrax protective antigen (PA); anthrax lethal factor (LF)
- Manufacturer: National Institutes of Health Clinical Center (CC) — full pipeline
- Therapeutic area: All drugs in Infectious Disease; Immunology
- Indication: Drugs for Inhalational anthrax (adjunctive therapy with antibiotics)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing